THQM Stock Overview
Engages in the development and manufacture of generic and in-licensed medicines in Bulgaria.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | лв17.30 |
| 52 Week High | лв17.40 |
| 52 Week Low | лв15.70 |
| Beta | 0.041 |
| 1 Month Change | -0.57% |
| 3 Month Change | 1.17% |
| 1 Year Change | 10.18% |
| 3 Year Change | 28.94% |
| 5 Year Change | 97.77% |
| Change since IPO | 627.06% |
Recent News & Updates
Shareholder Returns
| THQM | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | -0.6% | 2.2% | 2.0% |
| 1Y | 10.2% | 12.2% | 19.7% |
Return vs Industry: THQM underperformed the BG Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: THQM underperformed the BG Market which returned 19% over the past year.
Price Volatility
| THQM volatility | |
|---|---|
| THQM Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in BG Market | 8.0% |
| 10% least volatile stocks in BG Market | 2.1% |
Stable Share Price: THQM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine THQM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 199 | n/a | www.tchaikapharma.com |
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers anaesthetic, anti-inflammatory and anti-rheumatic, antibiotic, cardiovascular system, digestive system, diabetes and metabolism, nervous system, OTC, respiratory system, oncology, and other medicines. It also provides nutritional supplements.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
| THQM fundamental statistics | |
|---|---|
| Market cap | лв1.54b |
| Earnings (TTM) | лв2.93m |
| Revenue (TTM) | лв48.26m |
525.2x
P/E Ratio31.8x
P/S RatioIs THQM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| THQM income statement (TTM) | |
|---|---|
| Revenue | лв48.26m |
| Cost of Revenue | лв8.80m |
| Gross Profit | лв39.47m |
| Other Expenses | лв36.54m |
| Earnings | лв2.93m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.033 |
| Gross Margin | 81.77% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 9.2% |
How did THQM perform over the long term?
See historical performance and comparison